Roche Pegasys/Copegus Combination Pack Clears FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Company will continue to sell Pegasys (peginterferon alpha-2a) separately from Copegus (ribavirin). Availability of a co-packaged product could help lessen the likelihood that patients will combine Pegasys with generic ribavirin.
You may also be interested in...
Roche Pegasys sBLA Filing For Hepatitis B Could Receive Priority Review
Roche announced simultaneous U.S. and European submissions July 21; six-month review would set user fee date at mid-January. Roche is likely to highlight superiority to GlaxoSmithKline’s Epivir-HBV and efficacy in HBeAg-negative patients in promotions.
Roche Pegasys sBLA Filing For Hepatitis B Could Receive Priority Review
Roche announced simultaneous U.S. and European submissions July 21; six-month review would set user fee date at mid-January. Roche is likely to highlight superiority to GlaxoSmithKline’s Epivir-HBV and efficacy in HBeAg-negative patients in promotions.
Schering Generic Ribavirin Carries PEG-Intron Indication; Valeant Will Receive Royalties
Schering generic launches April 8, two days after FDA clears Three Rivers’ and Sandoz’ ribavirin ANDAs. All generics are expected to be priced at a 10% discount to Schering’s Rebetol.